ArticleMMWR. Morbidity and mortality weekly report2022
Progress Toward Polio Eradication - Worldwide, January 2020-April 2022.
Article in MMWR. Morbidity and mortality weekly report, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 60 citations in OpenAlex.
- Persistence of immunity following a single dose of inactivated poliovirus vaccine: a phase 4, open label, non-randomised clinical trial.The Lancet. Microbe · 2023Trial
- Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomised, controlled trial.The Lancet. Infectious diseases · 2023Trial
- Article
- The Current Status in Terms of Vaccination for Individuals Infected with Human Immunodeficiency Virus.Viruses · 2025Review
- Serological investigation on the prevalence of poliovirus in Guangdong province: A cross-sectional study.Human vaccines & immunotherapeutics · 2024Article
- Opportunities and challenges for T cell-based influenza vaccines.Nature reviews. Immunology · 2024Review
- Article
- Using machine learning algorithms to predict COVID-19 vaccine uptake: A year after the introduction of COVID-19 vaccines in Ghana.Vaccine: X · 2024Article
- Progress Toward Poliomyelitis Eradication - Worldwide, January 2022-December 2023.MMWR. Morbidity and mortality weekly report · 2024Article
- Worst-case scenarios: Modeling uncontrolled type 2 polio transmission.Risk analysis : an official publication of the Society for Risk Analysis · 2024Article
- Article
- Comprehensive profiling of neutralizing polyclonal sera targeting coxsackievirus B3.Nature communications · 2023Article
- Progress Toward Poliomyelitis Eradication - Afghanistan, January 2022-June 2023.MMWR. Morbidity and mortality weekly report · 2023Article
- Progress Toward Poliomyelitis Eradication - Pakistan, January 2022-June 2023.MMWR. Morbidity and mortality weekly report · 2023Article
- Polio vaccination activities in conflict-affected areas.Human vaccines & immunotherapeutics · 2023Review
- Response to Vaccine-Derived Polioviruses Detected through Environmental Surveillance, Guatemala, 2019.Emerging infectious diseases · 2023Review
- Surveillance To Track Progress Toward Poliomyelitis Eradication - Worldwide, 2021-2022.MMWR. Morbidity and mortality weekly report · 2023Article
- The Fight against Poliovirus Is Not Over.Microorganisms · 2023Review
- Progress Toward Poliomyelitis Eradication - Worldwide, January 2021-March 2023.MMWR. Morbidity and mortality weekly report · 2023Article
- Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2021-December 2022.MMWR. Morbidity and mortality weekly report · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 1988, the World Health Assembly established the Global Polio Eradication Initiative (GPEI). Since then, wild poliovirus (WPV) cases have decreased approximately 99.99%, and WPV types 2 and 3 have been declared eradicated. Only Afghanistan and Pakistan have never interrupted WPV type 1 (WPV1) transmission. This report describes global progress toward polio eradication during January 1, 2020-April 30, 2022, and updates previous reports (1,2). This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.* Five WPV1 cases were reported from Afghanistan and Pakistan in 2021, compared with 140 in 2020. In 2022 (as of May 5), three WPV1 cases had been reported: one from Afghanistan and two from Pakistan. WPV1 genetically linked to virus circulating in Pakistan was identified in Malawi in a child with paralysis onset in November 2021. Circulating vaccine-derived polioviruses (cVDPVs), with neurovirulence and transmissibility similar to that of WPV, emerge in populations with low immunity following prolonged circulation of Sabin strain oral poliovirus vaccine (OPV) (3). During January 2020-April 30, 2022, a total of 1,856 paralytic cVDPV cases were reported globally: 1,113 in 2020 and 688 in 2021, including cases in Afghanistan and Pakistan. In 2022 (as of May 5), 55 cVDPV cases had been reported. Intensified programmatic actions leading to more effective outbreak responses are needed to stop cVDPV transmission. The 2022-2026 GPEI Strategic Plan objective of ending WPV1 transmission by the end of 2023 is attainable (4). However, the risk for children being paralyzed by polio remains until all polioviruses, including WPV and cVDPV, are eradicated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.